AIMMUNE THERAPEUTICS, INC. (OTCMKTS:SVON) Files An 8-K Regulation FD Disclosure

AIMMUNE THERAPEUTICS, INC. (OTCMKTS:SVON) Files An 8-K Regulation FD Disclosure

Story continues below

Item7.01

Regulation FD Disclosure.

Spokespersons of Aimmune Therapeutics, Inc. (the Company) plan to
present the information in the presentation slides attached
hereto as Exhibit 99.1 at various investor and analyst meetings
scheduled during the week of January9, 2017.

The furnishing of the attached presentation is not an admission
as to the materiality of any information therein. The information
contained in the slides is summary information that is intended
to be considered in the context of more complete information
included in the Companys filings with the U.S. Securities and
Exchange Commission (the SEC) and other public announcements that
the Company has made and may make from time to time by press
release or otherwise. The Company undertakes no duty or
obligation to update or revise the information contained in this
report, although it may do so from time to time as its management
believes is appropriate. Any such updating may be made through
the filing of other reports or documents with the SEC, through
press releases or through other public disclosures. For important
information about forward looking statements, see the slide
titled Forward-looking Statements in Exhibit 99.1 attached
hereto.

The information in this Item7.01 of this Current Report on Form
8-K and Exhibit 99.1 attached hereto shall not be deemed filed
for purposes of Section18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that
section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information contained in this Item7.01 and
in the presentation attached as Exhibit 99.1 to this Current
Report shall not be incorporated by reference into any filing
with the SEC made by the Company, whether made before or after
the date hereof, regardless of any general incorporation language
in such filing.


Item9.01
Financial Statements and Exhibits.

(d) Exhibits.


Exhibit


No.


Description


99.1
Company slide presentation dated January9-13, 2017.


About AIMMUNE THERAPEUTICS, INC. (OTCMKTS:SVON)

Sevion Therapeutics, Inc. is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.

AIMMUNE THERAPEUTICS, INC. (OTCMKTS:SVON) Recent Trading Information

AIMMUNE THERAPEUTICS, INC. (OTCMKTS:SVON) closed its last trading session down -0.023 at 0.280 with 9,300 shares trading hands.

An ad to help with our costs